Netrin-1 overexpression is predictive of ovarian malignancies

Anastasios D. Papanastasiou; Georgios Pampalakis; Dionyssios Katsaros; Georgia Sotiropoulou

doi:10.18632/oncotarget.258

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Netrin-1 overexpression is predictive of ovarian malignancies

Anastasios D. Papanastasiou, Georgios Pampalakis, Dionyssios Katsaros and Georgia Sotiropoulou _

PDF | HTML | How to cite

Oncotarget. 2011; 2:363-367. https://doi.org/10.18632/oncotarget.258

Metrics: PDF 2681 views | HTML 3428 views | ?

Abstract

Anastasios D. Papanastasiou^1*, Georgios Pampalakis^1*, Dionyssios Katsaros², Georgia Sotiropoulou¹

¹ Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, 26500, Greece

² Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, University of Turin, Turin, Italy

^* These authors contributed equally

Keywords: Oncogene, cancer, kinase, BRAF V600E, drug resistance, proteomics

Received: April 4, 2011; Accepted: May 1, 2011; Published: May 2, 2011;

Correspondence:

Georgia Sotiropoulou, e-mail:

Abstract

Netrin-1 (NTN1) is functionally important for the development of the nervous system. Interestingly, few recent studies showed that NTN1 may also promote cancer by increasing survival and resistance of lung and breast cancer cells to apoptosis. Our purpose was to investigate whether NTN1 and its receptor DCC may be involved in ovarian cancer. The NTN1 and DCC mRNAs were quantified by real-time RT-PCR in normal (10), benign (8) and cancer (17) ovarian tissues. ALAS1 and TBP housekeeping genes were used for normalization. NTN1 was found overexpressed in 76% of ovarian cancer specimens (13/17) as compared to normal (0/10, p<0.004) and benign (1/8, p<0.008) samples. Increased NTN1 mRNA levels correlated with advanced tumor stage (stage III, n=8, 100%) and grade (grade 3, n=7, 100%). In contrast, DCC was found downregulated in 59% (10/17) of ovarian tumors tested but correlation was not significant when compared to normal or benign specimens. Here, we demonstrated that NTN1 may be involved in ovarian cancer as the expression of NTN1 mRNA is strongly upregulated in ovarian malignant tumors but not in benign tumors. The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 258

Publication Alerts

Research Papers:

Netrin-1 overexpression is predictive of ovarian malignancies

Abstract